October 23, 2020 — IBA, a leading provider of proton therapy solutions, will highlight how its Proteus solutions as well as its work with its partners are shaping the future of proton therapy during the Annual Meeting and exhibition of the American Society for Radiation Oncology (ASTRO) being held online October 22-29, 2020.
IBA is displaying the latest developments for its Proteus systems that will address the current and future needs of proton therapy centers. IBA’s comprehensive Motion Management package will help clinicians treat more indications more confidently. Additionally, IBA’s unique Proton Arc Therapy will enable clinicians to treat patients precisely, faster and more easily. Finally, IBA believes Flash Therapy using protons has the potential to radically change the radiation therapy landscape revolutionize cancer care in general.
With 59 centers sold and 36 centers treating patients on a daily basis, IBA has the largest and most knowledgeable proton therapy user community. Together with its clinical partners, IBA is proud to celebrate a truly significant milestone of over 100,000 patients treated on an IBA Proteus system. This unique accumulated technical and clinical expertise is openly shared within IBA’s network of users through regular user meetings, bringing together experienced users as well as new members in the IBA community.
Having an open vendor platform, IBA also integrates the solutions of key leading industrial partners to further improve clinical workflow, integration and the overall user experience.
IBA has a long-term collaboration with Philips in imaging, diagnostics and radiation therapy for comprehensive cancer treatment.
The long-standing collaboration with Elekta is allowing both companies to offer a full set of treatment modalities in radiation therapy. IBA is very excited about the upcoming innovations in the Elekta Treatment Planning Solution. Together with MOSAIQ OIS and MOSAIQ Plaza, this complete solution will provide a strong ecosystem to integrate Proton Therapy into radiation therapy departments. Close collaboration with RaySearch Laboratories has demonstrates a fully integrated proton therapy workflow integrating IBA’s Proteus solution with Advanced treatment planning system (TPS) RayStation and next-generation oncology information system (OIS) RayCare an at the University hospital of Leuven in Belgium, where patient treatments began in July.
Olivier Legrain, Chief Executive Officer of IBA commented: “We are immensely proud that IBA’s technology has now impacted over 100,000 lives, giving patients and their families a new hope for the future. We continue to pursue further innovation by developing new technologies that will allow us to provide increasingly high standards while reducing treatment costs. Our philosophy of openly sharing our technological expertise with our clinical and industrial partners makes us uniquely positioned to speed up the development and shape the future of proton therapy.”
For more information: www.iba-worldwide.com
October 07, 2026 
